Supernus Pharmaceuticals, Inc. (SUPN) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 9 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for SUPN is $61.67, representing a +23.1% upside from the current price of $50.11. Price targets range from a low of $55.00 to a high of $65.00.
